van de Leur J J, Vollaard E J, Janssen A J, Dofferhoff A S
Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Antimicrob Agents Chemother. 1995 May;39(5):1182-4. doi: 10.1128/AAC.39.5.1182.
Pefloxacin (400 mg twice daily) was administered orally for infection prophylaxis in neutropenic patients. Diffusible fecal pefloxacin concentration was determined by bioassay during 24 neutropenic periods. The median diffusible fecal pefloxacin concentration was 187 micrograms/g. This concentration was comparable with those found in volunteers following oral and intravenous administration of pefloxacin (400 mg twice daily) (median of 171 and 155 micrograms/g, respectively). From this study, it is concluded that pefloxacin administered orally results in a predictable high diffusible fecal concentration which leads to effective elimination of susceptible aerobic gram-negative bacilli from the colonic flora.
培氟沙星（每日两次，每次400毫克）口服用于中性粒细胞减少患者的感染预防。在24个中性粒细胞减少期通过生物测定法测定粪便中可扩散的培氟沙星浓度。粪便中可扩散培氟沙星浓度的中位数为187微克/克。该浓度与口服和静脉注射培氟沙星（每日两次，每次400毫克）的志愿者体内浓度相当（中位数分别为171和155微克/克）。从本研究得出结论，口服培氟沙星可产生可预测的高粪便可扩散浓度，从而有效清除结肠菌群中易感的需氧革兰氏阴性杆菌。
